Rob Davis, Merck CEO

No deal for Mer­ck and Seagen yet as talks stall over buy­out price — re­port

Two Mon­days have come and gone with­out Mer­ck’s hot­ly-ru­mored takeover of Seagen, keep­ing ob­servers wait­ing. And ac­cord­ing to a new Bloomberg re­port, that’s be­cause the two sides have yet to agree on a price.

Talks be­tween Mer­ck and Seagen have stalled over the ac­qui­si­tion price, the news wire re­port­ed, cit­ing anony­mous in­sid­ers. The dis­cus­sion could still re­sume and lead to a deal, they added, al­though it clear­ly al­so may not. Seagen shares tum­bled al­most 7% to $153 in light of the re­port.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.